Psychemedics Corp Liquidation Value

PMDI Medical Laboratories

Cash & Equivalents

$1.42M
As of 2024-12-31
Current Price: N/A

Key Metrics

Cash Liquidation Value

Cash minus Total Obligations
Cash: $1.42M
Total Obligations: -$3.13M
$-1.72M
Per share: $-0.28
Period: 2024-12-31
incomplete 2 components missing — treated as $0 in formula. Why?
  • Long-Term Debt: not reported in this period (annual-only)
  • Operating Lease Liability: not reported in this period (annual-only)

Liquid Liquidation Value

Cash + AR minus Total Obligations
Cash: $1.42M
AR: $2.50M
Total Obligations: -$3.13M
$782,000
Per share: $0.13
Period: 2024-12-31
incomplete 2 components missing — treated as $0 in formula. Why?
  • Long-Term Debt: not reported in this period (annual-only)
  • Operating Lease Liability: not reported in this period (annual-only)

Operating Liquidation Value

Cash + AR + Inventory minus Total Obligations
Cash: $1.42M
AR: $2.50M
Inventory: N/A
Total Obligations: -$3.13M
$782,000
Per share: $0.13
Period: 2024-12-31
incomplete 3 components missing — treated as $0 in formula. Why?
  • Long-Term Debt: not reported in this period (annual-only)
  • Operating Lease Liability: not reported in this period (annual-only)
  • Inventory: not reported

Build your own liquidation scenario

Adjust asset discounts and liability assumptions to see how assumptions affect the numbers.

Open Calculator →

Liquidation Ladder

MetricTotalPer Share
Cash Liquidation Value$-1.72M$-0.28
Liquid Liquidation Value$782,000$0.13
Operating Liquidation Value$782,000$0.13

Key Components (as of 2024-12-31)

Data as of 2024-12-31 from 10-K filed 2025-03-24. View on SEC EDGAR →

Cash & Equivalents$1.42M
Accounts Receivable$2.50M
InventoryN/A
Current Liabilities$2.71M
Long-term Debt (?)N/A
Op. Lease Liability (?)$424,000
Finance Lease (?)$53,000
Shares Outstanding6.1M

Explore all 175 XBRL tags and build your own scenario → Open Calculator

Historical

PeriodCashARInventoryAPCurr LiabLT DebtOp LeaseFin Lease
2024-12-31$1.42M$2.50MN/A$462,000$2.71MN/A$424,000$53,000
2024-09-30$1.41M$3.33MN/A$994,000$3.79MN/A$535,000$61,000
2024-06-30$1.43M$3.06MN/A$662,000$3.75MN/A$623,000N/A
2024-03-31$1.42M$3.88MN/A$1.13M$4.18MN/A$687,000N/A
2023-12-31$1.96M$3.69MN/A$752,000$4.71M$0$945,000$0
2023-09-30$1.37M$4.60MN/A$817,000$5.38M$77,000$1.21MN/A
2023-06-30$2.44M$4.00MN/A$806,000$5.64M$154,000$1.47MN/A
2023-03-31$4.38M$4.06MN/A$785,000$5.79M$230,000$1.72MN/A

Comments

SEC Filings

PeriodFormFiledLink
2024-12-31 10-K 2025-03-24 View
2024-09-30 10-Q 2024-11-12 View
2024-06-30 10-Q 2024-08-13 View
2024-03-31 10-Q 2024-05-14 View
2023-12-31 10-K 2024-03-28 View
2023-09-30 10-Q 2023-11-13 View
2023-06-30 10-Q 2023-08-14 View
2023-03-31 10-Q 2023-05-11 View

AI Insights

AI Insight·Generated 2026-05-06

Psychemedics Corp (PMDI) as of December 31, 2024 presents a micro-cap service business with constrained but positive book equity of $5.1 million against total assets of $8.3 million. Under a liquidation lens, recovery to equity is marginal and dependent almost entirely on liquid assets. The MFFAIS-computed cash liquidation value is negative at -$1.77 million, reflecting that liabilities at face value exceed haircut asset recoveries when cash is included. The liquid liquidation value of $0.73 million indicates a thin positive recovery only when viewed on a quick-asset basis excluding PP&E and intangibles. Cash and cash equivalents stand at $1.42 million (100% recovery), accounts receivable net at $2.5 million (90-95% recovery yields approximately $2.25-2.37 million), and prepaid/other current assets of $1.0 million (minimal recovery). PP&E net of $2.0 million ($24.2 million gross, $22.2 million accumulated depreciation) would recover 50-70%, or approximately $1.0-1.4 million, but the asset base is largely specialized laboratory equipment whose orderly liquidation value is uncertain. Capitalized software of approximately $5.9 million gross is carried net after amortization but would receive zero recovery under liquidation. Operating lease ROU assets ($844 thousand operating, $80 thousand finance) are balance-sheet fictions in liquidation; the corresponding liabilities of $876 thousand (operating) and $81 thousand (finance) remain at face value. Total liabilities of $3.19 million include $2.71 million current: accounts payable $462 thousand, accrued liabilities $1.56 million, operating lease current $452 thousand, short-term insurance note $209 thousand. The Banc of America equipment loan was fully repaid as of December 31, 2024, eliminating secured debt that was a covenant-waiver risk in prior periods. A material development since the prior 10-Q (September 30, 2024): the Company completed a going-private reverse/forward stock split transaction approved at the November 25, 2024 annual meeting, executed a stock sale to Peter Kamin's 3K Limited Partnership raising approximately $1.93 million at $2.35 per share, and repurchased fractional shares for approximately $2.56 million. Net cash position decreased by $547 thousand for the year. The Company changed auditors from BDO to Whitley Penn LLP in June 2024. A full valuation allowance of $2.66 million is maintained against net deferred tax assets, consistent with the three-year cumulative loss position. Accumulated deficit stands at $18.6 million. Treasury stock of $10.1 million (668 thousand shares) is a significant contra-equity item absorbing book value. No goodwill or identifiable intangibles separately disclosed beyond capitalized software. Filing discusses deferred tax asset valuation in MD&A but the going-private transaction's balance sheet impact (net cash reduction, share issuance proceeds, and buyback) is disclosed in the statement of equity rather than separately tagged as a single XBRL concept.

Flags

Loading flags...

AI Insight Discussion

Loading...

Community Notes

Loading notes...

Questions

Loading questions...